The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition-Reference-Cited by-同舟云学术

The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition

Published:2017-05-26 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Goodwin Justin,Neugent Michael L.,Lee Shin Yup,Choe Joshua H.,Choi Hyunsung,Jenkins Dana M. R.,Ruthenborg Robin J.,Robinson Maddox W.,Jeong Ji Yun,Wake Masaki,Abe Hajime,Takeda Norihiko,Endo Hiroko,Inoue Masahiro,Xuan Zhenyu^ORCID,Yoo Hyuntae,Chen Min^ORCID,Ahn Jung-Mo,Minna John D.,Helke Kristi L.,Singh Pankaj K.,Shackelford David B.,Kim Jung-whan

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms15503.pdf

Reference70 articles.

1. Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F. & Wong, K. K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14, 535–546 (2014).

2. Drilon, A., Rekhtman, N., Ladanyi, M. & Paik, P. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy. Lancet Oncol. 13, e418–e426 (2012).

3. Sun, S., Schiller, J. H., Spinola, M. & Minna, J. D. New molecularly targeted therapies for lung cancer. J. Clin. Invest. 117, 2740–2750 (2007).

4. Einhorn, L. H. First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J. Clin. Oncol. 26, 3485–3486 (2008).

5. Thatcher, N. et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol. 16, 763–774 (2015).

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non–Small Cell Lung Cancer. An Official American Thoracic Society Research Statement;American Journal of Respiratory and Critical Care Medicine;2024-09-01

2. Redirecting Tumor Evolution with Nanocompiler Precision for Enhanced Therapeutic Outcomes;Advanced Healthcare Materials;2024-07-23

3. Glycemic status, insulin resistance, and mortality from lung cancer among individuals with and without diabetes;Cancer & Metabolism;2024-06-20

4. Recent Advances in Molecular and Genetic Research on Uveal Melanoma;Cells;2024-06-12

5. Depletion of squalene epoxidase in synergy with glutathione peroxidase 4 inhibitor RSL3 overcomes oxidative stress resistance in lung squamous cell carcinoma;Precision Clinical Medicine;2024-05-01